CVS · NASDAQ · STOCK
CVS Health
$95.67
52W $64.32 – $110.68
51/100
$122.11B
25.0
0.60
Is CVS Bullish or Bearish?
Mixed.
Innellis AI committee rates CVS Health (CVS) Watch with a composite score of 51/100
, based on 6 analysts with 33% agreement.
Last updated August 08, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +8.64 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -11.36 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Macro Analyst sees a compelling case — market regime is bullish (bull market -- normal position sizing). Risk Analyst remains cautious — current ratio of 0.84 is tight -- limited short-term liquidity cushion. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Price-to-book of 1.3x is a discount to asset value — Value
- Dividend yield of 2.8% pays you to wait — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- P/E of 25.0 is moderate-to-rich — Value
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- RSI at 19 is in oversold territory (could mean either capitulation or a bounce setup) — Technical
- MACD histogram negative -- bearish momentum — Technical
- Price trading below the lower Bollinger Band -- stretched to the downside — Technical
- Current ratio of 0.84 is tight -- limited short-term liquidity cushion — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of August 08, 2026
Overall Committee Score
51/100
Agreement
33%
Analysts
6
Conviction
Contested
Sector Rank
Top 95%
of 95 Healthcare peers
Value Analyst
bullish
60
/ 100 · Moderate confidence
Classic value case: cheap on multiples with earnings power to back it up
+ Price-to-book of 1.3x is a discount to asset value
− P/E of 25.0 is moderate-to-rich
Growth Analyst
neutral
52
/ 100 · High confidence
Moderate growth -- present but not remarkable
+ 5 consecutive earnings beats -- consistent execution
− Growth rate is decelerating quarter over quarter -- the trend line matters more than the level
Technical Analyst
bearish
38
/ 100 · High confidence
Price action is deteriorating -- trend and/or momentum are working against this name
− RSI at 19 is in oversold territory (could mean either capitulation or a bounce setup)
Risk Analyst
bearish
35
/ 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− Current ratio of 0.84 is tight -- limited short-term liquidity cushion
Macro Analyst
bullish
70
/ 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst
neutral
53
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
neutral
55
/ 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 4 existing position pair(s) are highly correlated already
Investment Thesis Evolution
Committee score moved marginally from 53.0 to 51.4.
- New bearish signals: 2 appeared.
- Bearish pressure eased: 1 signal(s) disappeared.
Analyst-level changes:
- Technical Analyst: +1 bearish signal(s).
- Value Analyst: score 70->60 (-10); +1 bearish signal(s).
Comparing 2026-08-07 to 2026-08-08 (1 day apart).
Technical Analysis
RSI (14)
19.2
Oversold
MACD Histogram
-1.645
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Hh Hl
Support
$88.81
Resistance
$96.53
Bollinger %B
-0.11
Below Lower Band
Price vs Moving Averages
EMA 9
$101.37
Below
EMA 21
$103.32
Below
EMA 50
$100.77
Below
EMA 200
$87.29
Above
Fundamental Analysis
Valuation
53
Growth
75
Profitability
6
Financial Health
41
Cash Flow
70
Valuation
P/E Ratio
25.0×
P/B Ratio
1.53×
PEG Ratio
3.91
Dividend Yield
2.78%
52W High
$110.68
52W Low
$64.32
Quality & Growth
ROE
235.1%
ROA
67.7%
Gross Margin
1415.3%
Operating Margin
199.7%
Revenue Growth YoY
—
Debt / Equity
0.96
AI Fundamental Assessment
P/E ratio of 25.0 (inexpensive relative to a 15-40x range); Price-to-book of 1.5x; PEG ratio of 3.9 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 2.4%; Return on assets of 0.7%; Net margin of 1.2%; Gross margin of 14.2%; Current ratio of 0.87 (tight short-term liquidity); Debt-to-equity of 0.96; Free cash flow per share is positive (11.88); Most recent quarter beat estimates by 38.0%; 5 consecutive earnings beats; EPS growth decelerating (+135.8% -> +0.4% QoQ); Average YoY EPS growth of 42.5%; Analyst estimates rising over recent quarters
Get the Full CVS Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →